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Zusammenfassung
Der humane epidermale Wachstumsfaktor-Rezeptor-2
(HER2) wird in 15–25% der Mammakarzinome überexpri-
miert, üblicherweise auf dem Boden einer Genamplifika-
tion. Ein positiver HER2-Status gilt als ungünstiger Pro-
gnosefaktor. Die Aufdeckung der Rolle von HER2 im Tu-
morwachstum des Mammakarzinoms hat zu der Ent-
wicklung einer anti-HER2-gerichteten Therapie geführt.
Der humanisierte monoklonale Antikörper Trastuzumab
(Herceptin®) ist mittlerweile zur Behandlung des HER2-
positiven metastasierten Mammakarzinoms zugelassen.
Außerdem legen klinische Studien nahe, das HER2 wich-
tige prädiktive Informationen bezüglich des Erfolgs und
Versagens von bestimmten Hormon- und Chemothera-
pien liefern kann. Als Folge dieser Entwicklungen ist der
Bedarf an HER2-Bestimmungen in aktuellem und archi-
viertem Tumormaterial deutlich angestiegen. Dieser Arti-
kel gibt einen Überblick über den molekularen Hinter-
grund der Funktion, Aktivierung und Inhibition von HER2
sowie aktuelle Sichtweisen zu dessen Rolle im Hinblick
auf die Chemosensitivität und Interaktion mit der Biolo-
gie des Östrogenrezeptors. Die verschiedenen gewebe-
basierten Verfahren zum Nachweis einer HER2-Amplifi-
kation und -Überexpression werden im Hinblick auf ihre
Vor- und Nachteile diskutiert. Außerdem wird auf die Fra-
gen eingegangen, wann (bei Erstdiagnose oder unmittel-
bar vor einer Behandlung) und wo (lokal oder zentrali-
siert) die Bestimmung erfolgen sollte. Zusätzlich werden
Qualitätssicherungsmaßnahmen erläutert, die notwen-
dig sind, um genaue und valide Ergebnisse sicherzustel-
len.
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Summary
Human epidermal growth factor receptor 2 (HER2) is
overexpressed in 15–25% of breast cancers, usually as a
result of HER2 gene amplification. Positive HER2 status is
considered to be an adverse prognostic factor. Recogni-
tion of the role of HER2 in breast cancer growth has led
to the development of anti-HER2 directed therapy, with
the humanized monoclonal antibody trastuzumab (Her-
ceptin®) having been approved for the therapy of HER2-
positive metastatic breast cancer. Clinical studies have
further suggested that HER2 status can provide impor-
tant information regarding success or failure of certain
hormonal therapies or chemotherapies. As a result of
these developments, there has been increasing demand
to perform HER2 testing on current and archived breast
cancer specimens. This article reviews the molecular
background of HER2 function, activation and inhibition
as well as current opinions concerning its role in
chemosensitivity and interaction with estrogen receptor
biology. The different tissue-based assays used to detect
HER2 amplification and overexpression are discussed
with respect to their advantages and disadvantages,
when to test (at initial diagnosis or pre-treatment), where
to test (locally or centralized) and the need for quality as-
surance to ensure accurate and valid testing results.
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Introduction
The human epidermal growth factor receptor-2 (HER2) proto-
oncogene, also known as HER-2/neu or c-erbB2, is the human
analogue of the oncogenic mutant neu gene identified in rat
neuroblastomas in the early 1980s. Although this and other
HER2 mutations are rarely, if at all, observed in human can-
cers, wild-type HER2 has been found to be amplified at the
genomic level and/or overexpressed at the protein level in a
number of human cancers [1–4]. This subject has been most
extensively addressed in the domain of breast cancer in which
HER2 is overexpressed or amplified with a 15–25% incidence.
HER2 overexpression and amplification is associated with a
significantly shorter overall survival rate and time to relapse,
i.e. a worse prognosis, in breast cancer patients [5, 6]. An in-
creasing body of evidence also supports the role of HER2 as
an important predictive factor of response to chemotherapy
and hormonal therapy in breast cancer [7–11]. Consequently,
therapeutic agents that directly target HER2 protein have
been developed. Nowadays trastuzumab (rhuMAb 4D5, Her-
ceptin®, Genentech, South San Francisco, CA, USA) is the
agent with the most extensive available data from randomized
trials. Herceptin is a humanized monoclonal antibody (MAb)
that directly targets the extracellular domain of the HER2 re-
ceptor. It was approved for HER2-positive metastatic breast
cancer by the US Food and Drug Administration in 1998 and
in the member states of the European Union in 2000.
Because of the recently published promising interim efficacy
analyses of trials that added trastuzumab to adjuvant
chemotherapy in HER2-positive breast cancer, Herceptin is
going to be included in the adjuvant therapy of human breast
cancer [12, 13]. Therefore, the history of HER2 and Herceptin
can be seen as a successful example of translational research.
None of the recent developments in the understanding of the
molecular mechanisms underlying breast tumorigenesis has
had a greater impact on both clinicians and pathologists. Fur-
thermore, anti-HER2-directed therapy represents a model for
the future of targeted therapies not only in breast cancer. This
review will address the molecular basics of HER2 function,
activation and inhibition in breast cancer as well as the cur-
rently available and approved tissue-based methods for the as-
sessment of HER2 status, including the relevance of quality
assurance.
Molecular Background
Structure, Function and Activation of HER2
Located on chromosome 17q21, the HER2 proto-oncogene
encodes a 185-kDa glycoprotein, the HER2 protein or HER2
receptor. HER2 plays a key role in one of the best studied
growth factor receptor systems in breast cancer, the HER (or
erbB, or Type 1) tyrosine kinase receptor family. This family
comprises 4 homologous epidermal growth factor receptors,
HER1 (EGFR/erbB1), HER2 (erbB2), HER3 (erbB3) and
HER4 (erbB4), in which EGFR was the first to be molecular-
ly cloned [14]. Each of these receptors comprises an extracel-
lular ligand-binding domain, a transmembrane lipophilic seg-
ment and an intracellular protein kinase domain with a car-
boxyl terminal segment containing sites of phosphorylation or
tyrosine residues [1, 4, 11]. The HER family plays an impor-
tant role in regulating cell growth, survival and differentiation
in a complex manner. Various ligands have been identified
that activate individual HER receptors, although no ligand
has been found that directly binds to the HER2 receptor. In
common with many other growth factor receptors, members
of the HER family dimerize upon ligand stimulation and
transduce their signals by subsequent autophosphorylation
catalyzed by the receptor cytoplasmatic tyrosine kinase activi-
ty. HER receptor monomers form homodimers with the same
receptor or heterodimers with other members of the HER
family in response to ligand binding. HER2 is the preferred
heterodimerization partner within the family and can be stabi-
lized and transactivated in heterodimers by ligands for the
partner HER monomer, such as HER1 or HER3. This het-
erodimerization between HER2 and the other receptors of
the family allows HER2 to participate in signal transduction,
even in the absence of a cognate ligand. The type and ampli-
tude of activated downstream signaling cascades are influ-
enced by the type and number of receptors expressed by a
particular cell and the amount and type of ligand that stimu-
lates the cell.
In vitro and animal studies have indicated that HER2 gene
amplification and protein overexpression play a pivotal role in
oncogenic transformation, tumorigenesis and tumor progres-
sion. The normal epithelial cell possesses 2 copies of the
HER2 gene and expresses low levels of HER2 protein on the
cell surface, equivalent to some tens of thousands of receptors
per cell. With oncogenic transformation, HER2 gene amplifi-
cation generating more than the normal 2 gene copies is the
most common mechanism leading to 10–100-fold increases in
HER2 receptor monomers on the cell surface, i.e. HER2 over-
expression equivalent to millions of receptors. In some cases,
the extracellular domain of the HER2 receptor (ECDHER2)
may be shed from the cell surface and detected in the circula-
tion. Overexpression of HER2 appears to have a number of
effects that potentially result in carcinogenesis. The preferen-
tial formation of HER2-containing heterodimers leads to pro-
longed and enhanced downstream signaling due to increased
stability compared with other heterodimers, reduced ligand
dissociation and a decreased rate of endocytosis. When EGFR
heterodimerizes with HER2, it is increasingly recycled to the
cell surface, also resulting in intensified signaling. The forma-
tion of constitutively active homodimers may result in the ini-
tiation of downstream signaling pathways. On the basis of
these effects, HER2 amplification disrupts normal control
mechanisms by activation and suppression of numerous signal
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transduction pathways with potential roles in tumor develop-
ment and growth [1–3, 11].
HER2 and Response to Chemotherapy or Hormonal Therapy
HER2 status seems to influence the response to chemothera-
py and hormonal therapy. But the evaluation of clinical trials
has not been consistent, and the interpretation of these retro-
spective data is complicated and open to discussion. Never-
theless, most of the data suggest that a positive HER2 status
predicts the likelihood of resistance to some conventional
therapies, such as CMF (cyclophosphamide, methotrexate, 5-
fluorouracil), on the one hand, but an increased chemosensi-
tivity to anthracyclines on the other hand [11, 15]. However,
the molecular background of these potential interactions is
unclear. It has been suggested but not yet established that not
the HER2 amplification but the co-amplification of the topoi-
somerase II-alpha (Topo IIα) gene, which is located in the
vicinity of the HER2 gene on chromosome 17q21, might be
the predictive marker for responsiveness to anthracyclines.
Topo IIα is the known target for anthracyclines, and approxi-
mately 40% of breast cancers with HER2 amplification also
show amplification of the Topo IIα gene [16].
A range of studies have reported that patients with HER2-
overexpressing tumors respond poorly to treatment with the
selective estrogen receptor (ER) modulator (SERM) tamox-
ifen compared to patients with HER2-negative tumors [17].
In vitro evidence suggests that this effect is based on indirect
activation of the EGFR by ERs located in the plasma mem-
brane. A small pool of ERs seems to be located in the plasma
membrane and the cytoplasm. These ERs can mediate rapid
signals originating from the membrane, known as membrane-
initiated estrogen signaling (MISS). One potential mechanism
for the MISS activity involves indirect activation of the
EGFR. Dimerization of the EGFR with another receptor like
HER2 activates signaling pathways which in turn enhance nu-
clear ER signaling. In HER2-overexpressing tumors, a vicious
cycle may be established in which estrogen activates HER sig-
naling, and the HER signaling pathway further activates ERs.
SERMs, such as tamoxifen, activate membrane ER in a man-
ner similar to estrogen so that this molecular crosstalk might,
in part, explain the resistance to this agent and seems to have
important implications for the treatment of breast cancer. It is
thought that estrogen deprivation therapy with aromatase in-
hibitors is more effective than SERMs in HER2-positive tu-
mors as it shuts off not only the nuclear-initiated steroid sig-
naling but also the MISS activities of ER [18]. However, this
question can only be answered with additional large-scale,
long-term prospective studies taking into account the inverse
relationship between ER and progesterone receptor (PgR)
status and HER2 overexpression. Only approximately
11–35% of ER- and/or PgR-positive cases show HER2 over-
expression [6, 11, 19].
Targeting HER2 by Monoclonal Anti-HER2 Antibodies
Preclinical studies have demonstrated that the growth of
human tumors in mice and human breast cancer cell lines
overexpressing the HER2 receptor is inhibited by different
anti-HER2 MAbs. The rate of tumor regression depends on
the type of antibody. Whereas some antibodies almost com-
pletely abolish tumor growth, others are only partial antago-
nists. Some of the anti-HER2 MAbs were even found to en-
hance tumor volume [3]. The most efficient murine anti-
HER2 antibody to be developed was muMAb 4D5 (Genen-
tech) which was selected for further clinical development and
humanized to circumvent the anti-globulin response. The ther-
apeutic antibody Herceptin is the recombinant human anti-
HER2 MAb derived from muMAb 4D5. It binds to the jux-
tamembrane region of the HER2 ectodomain [20], a region
believed to be important for dimerization and transmembrane
signaling. Data clearly indicate that Herceptin markedly in-
hibits tumor growth in breast cancer xenografts overexpress-
ing HER2 unlike those not overexpressing HER2 [21–23].
The underlying mechanisms that mediate the anti-tumor ef-
fects are currently under investigation and have not yet been
fully elucidated. Available data suggest that the major mecha-
nisms include: i) acceleration of internalization and degrada-
tion of HER2 receptors from the cell membrane [3]; ii) re-
cruitment of immune cells to attack and kill target tumor cells
via antibody-dependent cell-mediated cytotoxicity [24–26]; iii)
inhibition of cleavage of the extracellular domain of the re-
ceptor by metalloproteinase, preventing homodimerization of
HER2 remnants and therefore antagonizing the constitutive
growth signaling [27, 28]; iv) inhibition of its downstream
phosphatidylinositol-3´-kinase(PI3K)-Akt pathway [29, 30]; v)
the induction of G1 arrest and the cyclin-dependent kinase in-
hibitor p27kip1 [27].
Clinical studies have demonstrated that Herceptin is well tol-
erated. It significantly improves survival of patients with
HER2-positive advanced metastatic breast cancer, particular-
ly in combination with chemotherapy [31, 32]. Despite careful
patient selection on the basis of HER2 assessment, the overall
Herceptin response rate is limited, especially if given as a sin-
gle agent [33, 34]. These observations suggest that HER2 gene
amplification and protein overexpression are necessary but
not sufficient for Herceptin responsiveness. Insights are limit-
ed, not least because the determinants of Herceptin response
are poorly understood. A recently published study suggests
that the efficacy of Herceptin is dependent on the ability to in-
hibit PIK3 signaling which is involved in the regulation of cel-
lular processes such as cell proliferation, survival and protein
synthesis [35]. Herceptin specifically downregulates PIK3 sig-
naling through activation of the tumor suppressor PTEN. Re-
sistance to Herceptin occurs when PTEN lipid phosphatase
function is lost, suggesting that PTEN activation is a critical
component of the therapeutic effect. Additionally, PI3K in-
hibitors rescue PTEN loss-induced Herceptin resistance, sug-
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gesting that PI3K-targeting therapies could overcome this re-
sistance. Although the investigators provided in vitro and in
vivo data that support their hypothesis, the results need fur-
ther validation including the analysis of PTEN expression in
correlation to the efficacy of Herceptin monotherapy.
Tissue-Based Assessment
Currently, there is great clinical demand for determining the
HER2 status of breast cancer cases, because of its impact on
treatment decisions for the patient. HER2 status obtained by
tissue-based testing is at present the only accepted predictive
marker for Herceptin therapy. Besides, HER2-positivity has
been added for assessment of endocrine responsiveness and
risk in the algorithm for selection of adjuvant systemic therapy
for early breast cancer patients at the ‘International Expert
Consensus on the Primary Therapy of Early Breast Cancer
2005’ in St. Gallen, Switzerland [36]. This underscores the
need for reliable and robust methodologies to determine the
HER2 status in breast cancer.
How to Test?
At least since the approval of Herceptin in the USA there has
been considerable confusion among clinicians and patholo-
gists with regard to which method and which reagents are
most appropriate for HER2 testing in routine clinical practice.
Herceptin is indicated for patients whose tumors have HER2
overexpression and/or amplification as determined by an ac-
curate and validated assay. Figure 1 illustrates the recom-
mended HER2 testing algorithm in accordance with the re-
quired preconditions for the use of Herceptin in Europe. Cur-
rently, the most frequently used HER2 testing methods are
immunohistochemistry (IHC) and fluorescence in situ hy-
bridization (FISH).
IHC employs antibodies specifically directed against an epi-
tope of the HER2 protein, thereby detecting HER2 on the
cell surface. It is optimal for usage on formalin-fixed, paraffin-
embedded tumor tissue which is the commonly used material
in clinical practice. It is performed in the majority of patholo-
gy laboratories and represents a highly sensitive and specific
technique if adequate antibodies and staining protocols are
applied. HER2 expression is recognized by a typical staining
pattern of the tumor cell membrane that is scored semiquanti-
tatively by the observer. The scoring system used in the Her-
ceptin pivotal trials is recommended in the guidelines for the
interpretation of the HercepTest™ kit (DakoCytomation,
Glostrup, Denmark). It is based on the percentage of positive
cells and the intensity of staining, giving a score range of 0–3+.
An IHC score of 3+ indicates an unequivocally positive result,
whereas 0/1+ are considered as negative.
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FISH allows the detection of HER2 gene amplification, the
initial genetic event that results in HER2 overexpression.
FISH can directly assess the HER2 gene copy number by
using labeled complementary DNA probes to detect HER2-
specific DNA sequences by hybridization. As with IHC,
FISH is performed on formalin-fixed, paraffin-embedded tis-
sue samples and also assesses the HER2 level on a cell-by-
cell basis. Because DNA is more stable than protein, FISH is
less affected by pre-analytical factors and handling of the tis-
sue than IHC. The results are evaluated by quantification of
the HER2 gene signals per tumor cell nucleus, complement-
ed by counting the chromosome 17 signals if a dual color
probe is used. According to the manufacturer’s guidelines,
HER2 gene amplification is either scored as an absolute
value (> 4 gene copies per nucleus; Inform®, HER-2/neu
test, Ventana Medical Systems, Tucson, AZ, USA) or as a
ratio of average HER2 copy number to that of chromosome
17 (ratio ≥ 2; PathVysion®, HER-2 test, Abbott, Abbott
Park, IL, USA).
Both methods are reliable, robust and highly specific when
adequately performed and have both been widely accepted as
the established standard HER2 testing methodologies. Nev-
ertheless, both methods are attended with advantages and
disadvantages. While IHC seems to be more susceptible to
variations in the handling of the tissue and testing protocols
as well as subjectivity in the scoring of immunoreactivity,
FISH represents a relatively costly technique in which signals
decay over time and occasional difficulties can occur when
identifying areas of invasive carcinoma by fluorescence mi-
croscopy. The reliability of both techniques can be assured by
use of validated assays and staining protocols under standard-
ized test conditions as well as adequate staff training. Thus, it
is preferable to use standardized tests, with the currently
available tests being HercepTest and Pathway™ HER-2
(Ventana Medical Systems, Tucson, AZ, USA) for IHC and
 
IHC                            FISH or CISH        
0, 1+ 2+ 3+ negative positive
negative positive
HERCEPTIN®
Re-test with
FISH or CISH
Tumor sample
Fig. 1. HER2 testing algorithm demonstrating identification of patients
eligible for Herceptin therapy (IHC = immunohistochemistry; FISH = flu-
orescence in situ hybridization; CISH = chromogenic in situ hybridization).
PathVysion and Inform for FISH. Tumors showing protein
overexpression by IHC scored 3+ and/or gene amplification
detected by FISH are termed HER2-positive. Patients with
HER2-positive tumors are eligible for Herceptin therapy.
Herceptin has been shown to provide most benefit in women
whose tumors overexpress the HER2 protein at the 3+ level
or demonstrate amplification of the HER2 gene. The concor-
dance rate between strong HER2 overexpression (score 3+)
and gene amplification detected by FISH is around 90%. Fur-
thermore, clinical outcomes are similar in IHC 3+ and FISH-
positive populations [31, 33, 34, 37]. A proportion of cases,
currently defined as equivocal by IHC (i.e. IHC score 2+)
also demonstrates gene amplification, but only in up to 25%
of tumors [38, 39]. Since some of these patients also respond-
ed to Herceptin in the pivotal trials [39], most of the national
testing guidelines recommend to retest all IHC 2+ tumors by
FISH [40].
Recently, chromogenic in situ hybridization (CISH) was intro-
duced for the detection of gene amplification. With CISH, the
HER2 gene is detected using a peroxidase enzyme-labeled
probe with a chromogenic detection instead of fluorescent
dye. As a consequence, technical equipment and costs are less
extensive compared with FISH. CISH-stained signals can be
viewed by standard light microscopy, histopathology of the
specimen can be assessed simultaneously, and the staining re-
mains stable over a long period of time [15, 41]. Currently, one
standardized test is commercially available for CISH (Zymed
SPoT-Light® HER2 CISH™ Kit, Invitrogen, South San Fran-
cisco, CA, USA). An international validation ring study has
demonstrated that CISH results are reproducible between
laboratories [42]. In the European Union, CISH is one of the
approved testing methods in the assessment of patients for
whom Herceptin treatment is being considered (Herceptin
Prescribing Information, 2004). However, there is a relative
lack of experience concerning the predictive value of CISH
except for one congress contribution that suggests a sensitivity
of CISH similar to FISH for predicting response to Herceptin
[43]. Even though comparative studies have reported a high
concordance (90–100%) between CISH and FISH and/or IHC
[15, 41, 44], CISH seems to be less sensitive in the case of low-
level amplification. Up to 43% of samples with low-level am-
plification detected by FISH are negative with CISH [42].
However, it should be noted that these cases occur at a low
frequency in the general population (1–3%) but at a higher
frequency in the critical group of IHC 2+ carcinomas (4–25%)
[38, 42, 45]. Nevertheless, whichever method or testing algo-
rithm is used to detect HER2 gene amplification or protein
overexpression, one has to bear in mind that the capability to
predict the response to Herceptin therapy is limited. There-
fore, the rigorous pursuit of the status of critical downstream
signaling molecules or alternative pathways in the tumors tar-
geted for Herceptin, alternative MAbs or HER2 small mole-
cule inhibitors should be a key aspect of the clinical approach
in HER2-positive breast cancer in the future [46].
When to Test?
Guidelines from the American Society of Clinical Oncology
(ASCO) recommend that HER overexpression should be
evaluated in every primary breast cancer patient, either at di-
agnosis or at the time of recurrence [47]. To date, it is becom-
ing more important that HER2 status is determined prospec-
tively so that it can be used as a prognostic and predictive fac-
tor to guide therapeutic possibilities [36, 48]. If the determina-
tion of HER2 status was to guide the administration of
adjuvant therapy, the analysis would clearly be required at the
time of diagnosis. However, advocates of delayed testing (i.e.
in metastatic disease, the setting in which Herceptin is cur-
rently licensed) point out the cost implications of testing all
patients at time of diagnosis. This is particularly true if FISH is
used for primary testing or re-testing of equivocal cases (i.e.
tumors scored 2+ by IHC). Thus, answering the question of
how to cover expenditure is becoming increasingly important.
However, there is also a practical argument for determining
and recording the HER2 status of samples at diagnosis, even if
it is not used before the disease recurs. There is huge variation
in national regulations on storing paraffin blocks: for example,
while there is no legal requirement in Germany, pathologists
in France and Canada are legally required to store blocks for
10 and 15 years, respectively. It is well known, that breast can-
cer can recur up to 20 years after the initial diagnosis [40].
Studies showing that HER2 status in the primary lesion re-
flects HER2 status of corresponding metastatic sites from the
same patient also support testing at first diagnosis. The level of
concordance between primary and metastatic sites ranges
from approximately 80 to 100% and generally exceeds 90%
[16]. Thus, early testing is the appropriate strategy to predict
the status of metastatic lesions so that taking biopsies from
metastatic patients is unnecessary if archival tissue of the pri-
mary tumor can be assessed [11].
Since core needle biopsies are increasingly performed within
the scope of primary diagnosis of breast cancer, they are also
increasingly used for the assessment of prognostic and predic-
tive markers, especially if primary (neoadjuvant) systemic
therapy is planned. Studies comparing the HER2 status in
needle biopsies and surgical specimen have reported an over-
all concordance of 91–100% using IHC alone [49–53]. Howev-
er, one investigation has presented data which suggest that the
validity of IHC score 3+ in core biopsies is limited [53]. Addi-
tional FISH analysis of the needle biopsy for those patients
who were HER2-negative (HercepTest score 0, 1+, 2+) in the
surgical specimen and HER-positive (HercepTest score 3+) in
the core biopsy confirmed the negative HER2 status of the
surgically removed tissue in 11 out of 13 cases (84.6%). Over-
all, among 57 patients showing HER2 overexpression by IHC
(HercepTest score 3+) in the core biopsies, 11 (19.3%) were
identified as false-positive on the basis of IHC analysis of the
surgical specimen and FISH. These results suggest that HER2
testing in surgical specimen is preferable if surgery is per-
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formed as primary therapy. If a pre-treatment core biopsy rep-
resents the only available tissue, additional FISH analysis may
be used in patients tested as HER2-positive (IHC score 3+) to
validate the HER2 status and to avoid anti-HER2-directed
therapy from which they are unlikely to benefit. However, it is
important to note, that the above mentioned results represent
data of a mono-institutional study so that large multi-institu-
tional studies will be necessary to clarify if additional FISH
analysis is actually required in case of carcinomas scored 3+ by
IHC in core biopsies. Furthermore, methodological aspects
which might explain the observed discrepancies should be in-
vestigated. Modifications in pre-analytical handling (i.e. fixa-
tion or embedding) of the core biopsies may be responsible
for the increased sensitivity of IHC.
Where to Test?
Where to test is a contentious issue. According to the license
of Herceptin in Europe, HER2 testing has to be performed in
specialized laboratories that ensure validation of the testing
methods so that reliable and reproducible results are ob-
tained. Advocates for centralized testing claim that laborato-
ries that are only processing a small number of samples annu-
ally cannot assure adequate quality of HER2 testing. Adher-
ing to strict quality control, quality assurance and validation
requires adequate equipment, standardized testing protocols
and continuous training. Centralized facilities assay greater
numbers of samples per year, leading to greater experience
and accuracy. Rigid quality control and validation add to the
level of accuracy. The higher accuracy of large-volume labora-
tories (≥ 100 assays per month) versus small-volume laborato-
ries can be exemplified by a report from the adjuvant Her-
ceptin trial led by the National Surgical Adjuvant Breast and
Bowel Project [54]. The accuracy of testing laboratories was
proven in 104 breast tumor samples by IHC and FISH in a
central reference laboratory. The frequency of false-positive
reporting was higher in small-volume laboratories, especially
in those that used ‘home-brew’ immunohistochemical tests in-
stead of standardized test kits. It was concluded that HER2
testing at a local laboratory by any assay other than FISH
would need to be validated at a large-volume center.
However, it is important to note that local testing centers offer
certain advantages. Results from local testing laboratories are
usually available quicker, with close contact between the
pathologist and the medical oncologist. In addition, tissue
samples are prepared in a homogenous manner at a local
level, for which interpretation of IHC testing can be more reli-
ably adapted for consistent results. Variability of tissue sam-
pling and fixation can be a source of interpretation error for
the heterogeneous samples received at central testing facili-
ties. Moreover, the results of national quality assurance pro-
grams offered by several national pathologists associations in-
dicate that the consistency and accuracy of local HER2 testing
can potentially reach a level similar to that of central testing
[16]. Requirements are the use of regular quality control/as-
surance programs and standardization of procedures. In addi-
tion, increased investment in education, training and experi-
ence exchange will help to achieve the goal, not only with re-
gard to HER2 testing but also the detection of other therapy
targets in the future.
Quality Control and Quality Assurance
Whichever method is used, accurate HER2 testing is essential
for optimal patient management with Herceptin. False-nega-
tive results may deny patients the chance of life-extending
therapy, while false-positive results waste resources, give rise
to false hopes and expose patients to unnecessary adverse ef-
fects. There are several factors that can contribute to inaccura-
cy of testing results in the clinical setting, including method of
tissue fixation, the assay method used, non-standardization of
procedures, intra- und interlaboratory variability and interob-
server variability. Thus, there should be standard operating
protocols for the used assays, and the initial validation of as-
says against a gold standard is mandatory for the maximiza-
tion of day-to-day and long-term accuracy. Moreover, internal
quality controls, including positive and negative controls,
should be included. Controls can be tissue arrays, tissue speci-
mens of known HER2 status or cell lines. A regular audit of
HER2-positive results in an unselected breast cancer popula-
tion is recommended to check that these are within the re-
ported limit (15–25%). If possible, the concordance between
IHC and FISH/CISH should be analyzed (IHC 3+ > 90%
FISH/CISH-positive; IHC 2+ ≤ 25% FISH/CISH-positive). If
there is an equivocal result, testing should be repeated, or
retesting by another method, such as FISH, should be per-
formed, if necessary in an external laboratory. Education and
experience in practical interpretation of assay results is essen-
tial to avoid misinterpretation of artifacts and to minimize un-
certainty at cut-off points, i.e. 2+/3+ cut-off. Staff training can
also improve the performance of HER2 testing accuracy. Ex-
ternal quality assessment procedures should be regularly im-
plemented. Quality assurance can include regular circulation
of test samples to other laboratories, i.e. reference testing lab-
oratories, for confirmation of the testing results by the same or
another method or participation in ring studies [16, 40].
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